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A B S T R A C T
Objectives: This study addresses the incidence, trends, and impact of nosocomial infections (NI) on the out-
comes of patients admitted with ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock
(STEMI-CS) using the United States National Inpatient Sample (NIS) database.
Methods: We analyzed data from 105,184 STEMI-CS patients using the NIS database from the years 2005-
2014. NI was defined as infections of more than or equal to three days, comprising of central line-associated
bloodstream infection (CLABSI), urinary tract infection (UTI), hospital-acquired pneumonia (HAP), Clostridium
difficile infection (CDI), bacteremia, and skin related infections. Outcomes of the impact of NI on STEMI-CS
included in-hospital mortality, length of hospital stay (LOS) and costs. Significant associations of NI in
patients admitted with STEMI-CS were also identified.
Results: Overall, 19.1% (20,137) of patients admitted with STEMI-CS developed NI. Trends of NI have
decreased from 2005-2014. The most common NI were UTI (9.2%), followed by HAP (6.8%), CLABSI (1.5%),
bacteremia (1.5%), skin related infections (1.5%), and CDI (1.3%). The strongest association of developing a NI
was increasing LOS (7-9 days; OR: 1.99; 95% CI: 1.75-2.26; >9 days; OR: 4.51; 95% CI: 4.04-5.04 compared to
4-6 days as reference). Increased mortality risk among patients with NI was significant, especially those with
sepsis-associated NI compared to those without sepsis (OR: 2.95; 95% CI: 2.72-3.20). Patients with NI were
found to be associated with significantly longer LOS and higher costs, irrespective of percutaneous mechani-
cal circulatory support placement.
Conclusions: NI were common among patients with STEMI-CS. Those who developed NI were at a greater risk
of in-hospital mortality, increased LOS and costs.
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Abbreviations and Acronyms: STEMI, ST-elevated myocardial infarction; STEMI-CS, cardiogenic shock following ST-elevated myocardial infarction; pMCS, percutaneous mechanical
circulatory support; NIS, National Inpatient Sample; AHRQ, Agency of Healthcare Research and Quality; ICD-9-CM, International Classification of Diseases - 9th Clinical Modification;
IABP, Intra-aortic balloon pump; PVAD, percutaneous ventricular assist device; ECMO, extracorporeal membrane oxygenation
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Nosocomial infections (NI) complicating hospitalizations for car-
diovascular diseases are associated with increased healthcare costs,
length of stay and in-hospital mortality.1,2 Cardiogenic shock (CS) fol-
lowing ST-elevation myocardial infarction (STEMI-CS) is frequently
accompanied by a noninfectious systemic inflammatory response.1,3
The degree of overlap of this response with an early infectious com-
plication is unclear, thus making the detection of a coexisting infec-
tion difficult.1 Rates of infections in non-CS patients with STEMI
following cardiac interventions such as cardiac catheterization and
percutaneous coronary interventions have been reported to be
<1%.4,5 However, these rates are probably higher in patients with CS,
in particular those requiring percutaneous mechanical circulatory
support (pMCS).2,6,7 Furthermore, despite the major advances in
device technology and caring for critically ill patients, the overall in-
hospital mortality rates among patients with CS are still elevated
(27%-51%).8 While the cause of mortality in these patients is likely
multifactorial, NI have been reported to play a major role. In fact, a
recent analysis of observational US data showed that having only one
NI increased the absolute risk of in-hospital mortality by 8.9% in
patients with CS. In addition, CS has been identified as the most com-
mon diagnosis linked to NI (4%) in the same study.2 CS has also been
previously identified as a predisposing factor for NI.3,9 Moreover, sep-
sis has been described as the most common non-cardiac cause of
death in patients hospitalized with CS.10
To date, only few large studies have evaluated the incidence and
impact of NI on outcomes of patients with STEMI-CS. The objectives
of this study are to: (1) assess the incidence of NI in STEMI-CS
patients; and (2) compare the healthcare costs, length of stay, and in-




The National Inpatient Sample (NIS) database was established by
the Agency of Healthcare Research and Quality (AHRQ). It presents a
sample of 20% of all inpatient discharges across different hospitals in
the United States.11 It provides the public with data on individual
hospitalizations. The data includes patient’s age and gender, length of
hospital stay, cost of hospitalization, mortality rates, comorbidities,
in-hospital complications, in-hospital procedures and type of admis-
sion (i.e. emergency or elective). The data used in this retrospective
cohort were from the years 2005 to 2014, inclusive. Recently, the
AHRQ issued a change in the NIS design and how patient discharges
are weighed to provide closer national estimates when performing
trend analysis.11,12 The new variable “Trend Weights” was developed
for years 2012 and beyond. It is also well-adjusted for previous years.
This method ensured the same level of patient analysis across all the
years.11,12
Study population, variables, and outcomes
Patients with STEMI and CS were identified using the interna-
tional classification of diseases, ninth revision, clinical modification
(ICD-9-CM) of “410.x1” for STEMI as the primary reason of admission
and 785.51 for CS as secondary diagnosis. Patients who were admit-
ted for non-STEMI using the diagnostic code of 410.7x were excluded
so that our analysis is limited to patients admitted with STEMI. The
ICD-9 codes for STEMI and CS have been validated in using adminis-
trative databases.13-16 Online Fig. 1 summarizes our sample selection
methodology. The ICD-9 code for STEMI had a sensitivity, specificity,
negative and positive predictive value of 72.4%, 99.5%, 96.1% and
95.9%, respectively.17 On the other hand, the ICD-9 code for CS was
found to have a sensitivity, specificity, negative and positive predic-
tive value of 59.8%, 99.3%, 98.1%, and 78.8%, respectively.14 Patients
with pMCS, such as the intra-aortic balloon pump (IABP), percutane-
ous ventricular assist device (PVAD) (eg, Impella and TandemHeart),
and extracorporeal membrane oxygenation (ECMO) were identified.
NI are defined as infections that occur during a patient’s hospital stay
duration of at least two days, with hospital-acquired pneumonia
(HAP) up to three days since admission.18,19 In our analysis, patients
who had a length of hospital stay of less than three days were
excluded. We identified patients with NI as having any of the follow-
ing infections during hospitalization: central line-associated blood-
stream infection (CLABSI), urinary tract infection (UTI), HAP,
Clostridium difficile infection (CDI), bacteremia, and skin related infec-
tions. To ensure that placement of pMCS was done prior to develop-
ment of a NI, time to procedure analysis was performed (Fig. 1).
Moreover, patients whose hospital stay was complicated by sepsis
were identified using the ICD-9-CM/clinical classification of diseases
(CCS) codes as highlighted in Online Tables 1 and 2. Patients younger
than 18 years of age, transferred to a different facility, those with
missing outcomes, age, or gender, were excluded from the analysis.
Demographic characteristics (ie, age, gender, and race), along with
comorbidities and procedures, were included in our analysis. Chronic
comorbidities, such as hypertension, liver disease, and obesity, were
obtained using the CCS software and Elixhauser comorbidity classifi-
cation (Online Tables 1 and 2). Patients were then grouped as shown
in Table 1 along with other details of the ICD-9-CM/CCS codes that
were used according to Online Tables 1 and 2.
Statistical analysis
For our analysis, we adhered to the main practices proposed by
Khera et al. on statistical and research methodologies using the NIS
Fig. 1. Timing of pMCS placement in STEMI-CS.
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database.20 Trend weights were used to estimate national hospital-
izations. Stratification and clustering data were done to provide
national estimates. For trend analysis, we reported hospitalizations
and outcomes as absolute values for each calendar year and com-
pared means using one-way ANOVA. First, we looked at the baseline
characteristics of STEMI-CS patients with and without NI. Subse-
quently, we compared baseline demographics and comorbidities
between groups using the Pearson x2 test for categorical variables
and one-way linear regression for continuous variables. We reported
categorical and continuous variables as percentages and mean §
standard error (SE), respectively. Incidence of NI and mortality based
on each subtype of NI and use of pMCS were then identified. We then
performed multivariable logistic regression analysis to identify varia-
bles that were highly associated with developing NI after controlling
for age, gender, race, hospital demographics and comorbidities. Fur-
thermore, to assess the impact of NI as a significant risk factor for
mortality, increased length of hospital stay and hospital costs across
patients admitted with STEMI-CS, multivariable logistic and linear
regression were done with NI as an independent predictor. Moreover,
similar subgroup analysis was performed amongst those with NI with
and without sepsis. Finally, trends of the incidence of NI in patients
admitted with STEMI-CS with and without pMCS were computed
using a Poisson regression model with a robust error variance to eval-
uate for changes in the number of outcomes (incidence of NI) per year
stratified by use of pMCS while inserting the year variable into the
model assuming the association to be linear. All data extraction and
analyses were performed using SPSS (Version 25.0 Armonk, NY).
Two-sided p-value <0.05 was used for statistical significance.
Results
A total of 172,490 patients with STEMI-CS were identified, with
28.9% and 71.1% had hospital stays of less than or equal to three days
and more than three days from the years 2005 to 2014, respectively.
The mortality rate of patients who were admitted with less than or
equal to three days and more than three days was 61.6% and 17.4%,
Table 1
Baseline characteristics of STEMI-CS patients with and without nosocomial infections.
Nosocomial infections
Total No infection Infection p-value*
No. of observations (weighted) (%) 105184 85046 (80.9) 20137 (19.1)
Demographic characteristic
Age, yrs (mean§SE) 65.1§12.9 64.8§12.9 66.9§13.1 <0.001
Males 69293 (65.9) 57877 (68.1) 11416 (56.7) <0.001
Females 35890 (34.1) 27169 (31.9) 8721 (43.3)
Race
White 66113 (62.9) 53575 (63.0) 12538 (62.3) <0.001
Black 5870 (5.6) 4638 (5.5) 1232 (6.1)
Hispanic 7018 (6.7) 5545 (6.5) 1473 (7.3)
Length of hospital stay
4-6 days 36230 (34.4) 33242 (39.1) 2988 (14.8)
7-9 days 24891 (23.7) 21083 (24.8) 3808 (18.9) <0.001
>9 days 44062 (41.9) 30721 (36.1) 13341 (66.3)
Comorbidities (%)
Anemia 21129 (20.1) 16226 (19.1) 4903 (24.3) <0.001
Hypertension 52111(49.5) 42795 (50.3) 9316 (46.3) <0.001
Diabetes 30836 (29.3) 24402 (28.7) 6434 (32.0) <0.001
Chronic liver disease 1293 (1.2) 976 (1.1) 317 (1.6) <0.001
Obesity 10254 (9.7) 8389 (9.9) 1865 (9.3) <0.001
Chronic pulmonary disease 22991 (21.9) 18603 (21.9) 4388 (21.8) 0.08
History of CVA 3543 (3.4) 2887 (3.4) 656 (3.3) 0.3
History of paralysis 1684 (1.6) 1189 (1.4) 495 (2.5) <0.001
Pulmonary circulation disorders 262(0.2) 111(0.1) 151(0.7) <0.001
Congestive heart failure 3090 (2.9) 1649 (1.9) 1441 (7.2) <0.001
Valvular disease 864 (0.8) 486 (0.6) 378 (1.9) <0.001
Cardiac arrhythmia 50858 (48.4) 40621 (47.8) 10237 (50.8) <0.001
Coagulopathy 15652 (14.9) 11810 (13.9) 3842 (19.1) <0.001
Chronic kidney disease 14454 (13.7) 11050 (13.0) 3404 (16.9) <0.001
Fluid and electrolyte disorders 42760 (40.7) 32688 (38.4) 10072 (50.0) <0.001
Peripheral vascular disease 9806 (9.3) 7782 (9.2) 2024 (10.1) 0.001
Alcohol abuse 4754 (4.5) 3849 (4.5) 905 (4.5) 0.9
Malignancy 2487 (2.4) 2031 (2.4) 456 (2.3) 0.2
Acquired immune deficiency syndrome 149 (0.1) 101 (0.1) 48 (0.2) <0.001
Rheumatoid arthritis/collagen vascular
disease
1937(1.8) 1520 (1.8) 417 (2.1) <0.001
Hypothyroidism 6938 (6.6) 5567 (6.5) 1371 (6.8) 0.002
Weight loss 6409 (6.1) 4315 (5.1) 2094 (10.4) <0.001
Elixhauser comorbidity index (%)
0 34759 (33.0) 29341 (34.5) 5418 (26.9) <0.001
1-3 46065 (43.8) 37582 (44.2) 8483 (42.1)
4 24360 (23.2) 18123 (21.3) 6237 (31.0)
Revascularization methods (%)
CABG 20789 (19.8) 16992 (20.0) 3797 (18.9) <0.001
PCI 72223 (68.7) 59088 (69.5) 13135 (65.2) <0.001
Fibrinolytic therapy 2095 (2.0) 1762 (2.1) 333 (1.7) 0.003
Vasopressor use (%) 6027 (5.7) 4738 (5.6) 1289 (6.4) <0.001
CVA: cerebrovascular accident.
CABG: coronary artery bypass graft surgery.
PCI: percutaneous coronary intervention.
* p-value <0.05 considered significant.
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respectively. After excluding patients with less than or equal to three
days, 105,184 hospitalizations for STEMI-CS were identified. Among
those, 20,137 had a NI (19.1%), with a mean age of 65.1 years (§ 12.9
years). Those admitted for STEMI-CS found to have a NI were pre-
dominantly males (56.7% vs 43.3%, p<0.001) and Whites (62.9%).
STEMI-CS patients who developed a NI were more likely to have
other comorbidities such as anemia (24.6% vs 16.6%, p<0.001), diabe-
tes mellitus (32.3% vs 28.7%, p<0.001), fluid and electrolyte disorders
(50.5% vs 38.7%, p<0.001), and chronic kidney disease (18.0% vs
13.8%, p<0.001).
Nosocomial infections among STEMI-CS patients
No significant difference was observed in the incidence of total NI
among patients admitted with STEMI-CS with and without pMCS
(19.3% vs 18.9%, p = 0.2) (Table 2, Fig. 2). Among those with pMCS, the
incidence of NI in patients with IABP, PVAD, and ECMO was 19.1%,
22.5%, and 28.7%, respectively. Those with more than one pMCS had a
23.8% rate of NI. The most common NI among patients with STEMI-CS
was UTI (9.2%) followed by HAP (6.8%), CLABSI (1.5%), bacteremia
(1.5%), skin related infections (1.5%), and CDI (1.3%) (Table 2, Fig. 2).
Moreover, HAP (18.0%), CDI (5.5%), CLABSI (5.1%), and skin related
infections (3.7%) were highest among patients placed on ECMO,
whereas UTI (9.7%) and bacteremia (2.8%) were highest among those
on PVAD (Table 3). The incidence of NI among admissions for STEMI-
CS decreased from the year 2005 to 2014, irrespective of pMCS use
(p<0.001) (Fig. 3). Fig. 4 presents the factors that were highly associ-
ated with greater odds of NI among STEMI-CS admissions. These
were: female gender (OR: 1.82; 95% CI: 1.75-1.86); increasing length
of hospital stay (7-9 days; OR: 1.99; 95% CI: 1.75-2.26; >9 days; OR:
4.51; 95% CI: 4.04-5.04 compared to 4-6 days as reference); history of
chronic liver disease (OR: 1.44; 95% CI: 1.06-1.98), pulmonary circula-
tion disorders (OR: 1.94; 95% CI: 1.04-3.61), fluid and electrolyte dis-
orders (OR: 1.27; 95% CI: 1.16-1.40); history of congestive heart
failure (OR: 2.19; 95% CI: 1.75-2.73); and chronic kidney disease (OR:
1.16; 95% CI: 1.03-1.31).
Incidence of mortality by type of nosocomial infection and mechanical
circulatory support
Tables 3 and 4 present the incidence of mortality among patients
with STEMI-CS with different NI, stratified by use of different pMCS.
Fig. 2. Difference in the incidence of nosocomial infections and mortality associated with nosocomial infections between STEMI-CS patients without pMCS and with any pMCS.
Table 2
Incidence of nosocomial infections and mortality based on use of pMCS.










Total infections 20137 (19.1) 8052 (18.9) 12085 (19.3) 0.2 16245 (21.8) 7459 (23.5) 8786 (20.6) <0.0001
CLABSI 1314 (1.2) 397 (0.6) 931 (1.2) <0.001 353 (26.9) 102 (26.0) 251 (27.3) 0.6
UTI 10744 (10.2) 6282 (9.0) 6123 (7.7) <0.001 2310 (21.5) 1176 (23.4) 1134 (19.8) <0.001
HAP 6326 (6.0) 1968 (2.8) 4449 (5.6) <0.001 1700 (26.9) 488 (25.7) 1212 (27.4) 0.2
CDI 1387 (1.3) 596 (0.9) 863 (1.1) 0.4 373 (26.9) 143 (26.2) 230 (27.3) 0.7
Bacteremia 1494 (1.4) 518 (1.2) 976 (1.6) <0.001 261 (17.5) 105 (20.3) 156 (16.0) 0.04
Skin-related wound
infections
1502 (1.4) 577 (1.4) 925 (1.5) 0.1 177 (11.8) 85 (14.7) 92 (9.9) 0.005
STEMI-CS: cardiogenic shock associated with ST-elevated myocardial infarction.
pMCS: percutaneous mechanical circulatory support.
IABP: intra-aortic balloon pump.
PVAD: percutaneous assist ventricular device.
ECMO: extracorporeal membrane oxygenation.
CLABSI: central line-associated bloodstream infection.
UTI: urinary tract infection.
HAP: Hospital-associated pneumonia.
CDI: C. difficile infection.
* p-value <0.05 considered significant.
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The mortality rate was 21.8% among those who developed a NI. The
incidence of death was lower in patients on pMCS compared to those
not on any pMCS (20.6% vs 23.5%, p<0.001).
Impact of nosocomial infections on mortality, length of hospital stay, and
average cost of hospitalization
NI were associated with higher risk of in-hospital mortality
(adjusted OR: 1.11, 95% CI: 1.07-1.16) and increased length of hospi-
tal stay (17 vs 10 days, p<0.001) and cost ($216,540 vs $151,932,
p<0.001). When stratified by pMCS, the incidence of NI was found to
be an independent predictor of mortality among those with IABP
(adjusted OR: 1.19, 95% CI: 1.13-1.26) and those with more than one
pMCS (adjusted OR: 2.20, 95% CI: 1.50-3.33). No increased risk of
mortality was found in patients who were not on any pMCS, PVAD,
or ECMO (Table 3).
Moreover, average length of hospital stay was higher in those who
developed a NI, especially among those on ECMO (38 days vs 13 days,
p<0.001) and more than one pMCS (33 vs 15 days, p<0.001). Simi-
larly, a higher average cost of hospitalization was found among those
who developed a NI, irrespective of pMCS.
Table 3
Incidence of nosocomial infections and mortality by subtype of pMCS used.


















Total infections 11501 (19.1) 237 (22.5) 78 (28.7) 240 (23.8) <0.001 8022(19.5) 227 (32.0) 122 (71.8) 361 (62.8) <0.001
CLABSI 875 (1.5) 5 (0.5) 14 (5.1) 27 (2.7) 223 (25.5) 0 (0.0) 14 (100.0) 13 (48.1) <0.001
UTI 5536 (9.2) 102 (9.7) 19 (7.0) 72 (7.1) 1051 (19.0) 29 (28.4) 5 (26.3) 49 (68.1) <0.001
HAP 4106 (6.8) 124 (11.8) 49 (18.0) 121 (12.0) 1061 (25.8) 55 (44.4) 20 (40.8) 62 (51.7) <0.001
CDI 780 (1.3) 5 (0.5) 15 (5.5) 43 (4.3) 197 (25.3) 0 (0.0) 15 (100.0) 18 (41.9) <0.001
Bacteremia 913 (1.5) 30 (2.8) 5 (1.8) 24 (2.4) 137 (15.0) 10 (33.3) 0 (0.0) 9 (37.5) 0.001
Skin related wound
infections
876 (1.5) 26 (2.5) 10 (3.7) 14 (1.4) 77 (8.8) 5 (19.2) 5 (50.0) 5 (35.7) <0.001
STEMI-CS: cardiogenic shock associated with ST-elevated myocardial infarction.
pMCS: percutaneous mechanical circulatory support.
IABP: intra-aortic balloon pump.
PVAD: percutaneous assist ventricular device.
ECMO: extracorporeal membrane oxygenation.
CLABSI: central line-associated bloodstream infection.
UTI: urinary tract infection.
HAP: Hospital-associated pneumonia.
CDI: C. difficile infection
* p-value <0.05 considered significant.
Fig. 3. Trends of nosocomial infection based on use of pMCS. Fig. 4. Variables highly associated with nosocomial infection in STEMI-CS.
Table 4
Impact of nosocomial infections on mortality, length of hospital stay, and average cost stratified by use of pMCS.
Type of population In-hospital mortality Length of hospital stay Average cost of hospitalization
Unadjusted odds ratio (95% CI) Adjusteda odds ratio (95% CI) No infection Infection p-value No infection Infection p-value
STEMI-CS 1.21 [1.16-1.25] 1.11 [1.07-1.16] 10 17 <0.001 151,932 216,540 <0.001
No pMCS 1.13 [1.06-1.19] 1.05 [0.99-1.12] 9 15 <0.001 124,244 168,456 <0.001
IABP 1.27 [1.21-1.34] 1.19 [1.13-1.26] 10 18 <0.001 163,044 231,394 <0.001
PVAD 1.18 [0.87-1.61] 0.92 [0.59-1.45] 10 21 <0.001 278,499 444,062 <0.001
ECMO 0.20 [0.12-0.36] 0.10 [0.02-0.33] 13 38 <0.001 481,860 636,704 0.003
Combined pMCS 1.16 [0.87-1.55] 2.20 [1.50-3.33] 15 33 <0.001 466,580 774,809 <0.001
STEMI-CS: cardiogenic shock associated with ST-elevated myocardial infarction.
pMCS: percutaneous mechanical circulatory support.
IABP: intra-aortic balloon pump.
PVAD: percutaneous assist ventricular device.
ECMO: extracorporeal membrane oxygenation.
a After adjusting for age, gender, race, comorbidities, hospital characteristics, and nosocomial infections.
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Sepsis in admitted STEMI-CS patients
We performed a subgroup analysis to further investigate the role
of sepsis in STEMI-CS patients admitted with a NI. During the 10-year
period from 2005 to 2014, 3,987 STEMI-CS hospitalizations with NI-
associated sepsis were identified, accounting for 19.8% among
STEMI-CS hospitalizations with NI (Online Table 3). The mean age for
STEMI-CS patients hospitalized with NI-associated with sepsis was
66.7 years (§ 13.3 years). Those who developed NI-associated sepsis
were predominantly males (61.7% vs 38.3%, p < 0.001) and Whites
(59.4%). STEMI-CS patients who developed NI-associated sepsis were
more likely to have the following comorbidities: diabetes (34.9% vs
31.3%, p<0.001), pulmonary circulation disorders (1.2% vs 0.6%,
p<0.001), congestive heart failure (13.1% vs 5.7%, p < 0.001), valvular
disease (3.4% vs 1.5%, p < 0.001), coagulopathy (25.2% vs 17.6,
p<0.001), fluid and electrolyte disorders (58.8% vs 47.8%, p<0.001),
and weight loss (14.5% vs 9.4%, p < 0.001).
Compared to those who did not develop sepsis, those who devel-
oped NI-associated sepsis had greater odds of in-hospital mortality
(OR: 2.95; 95% CI: 2.62-3.05), increased length of hospital stay
(23 days vs 16 days, p<0.001), and a higher average cost of hospitali-
zation (p<0.001) (Online Table 4). There was no difference in the inci-
dence of NI-associated sepsis between patients on pMCS and without
pMCS (p = 0.05), however mortality rates were higher among patients
on pMCS (41% vs 36.8%, p = 0.009) (Online Table 5). Moreover, among
deceased patients, the incidence of sepsis was highest in those with
more than one pMCS (61.5%), followed by PVAD (47.4%), ECMO
(50.0%), IABP (39.6%), and without pMCS (36.8%) (Online Table 6).
Baseline characteristics of STEMI-CS patients with and without NI
were then stratified by subtype of pMCS used as highlighted in Online
Table 7.
Discussion
In this study, we used the NIS database to investigate the role of
NIs in the context of STEMI-CS. In a study by Miller et al., CS was the
most common cardiovascular condition associated with healthcare-
acquired infection (HAI) accounting for 4% of admitted patients.2 In
our study, the most common NI were UTI, HAP, and CLABSI followed
by bloodstream infection, skin related infections and CDI in admitted
STEMI-CS patients. In contrast, in Miller et al.’s study, the most com-
mon HAI, among patients with heart failure, acute myocardial infarc-
tion, CS, CABG, and atrial fibrillation or flutter, were CDI followed by
catheter-associated UTI, ventilator-associated pneumonia, and
CLABSI.2 However, these were not stratified according to each cardio-
vascular condition. Another reason includes using lesser codes for
defining hospital acquired pneumonia. For example, in our study, we
defined HAP using codes for ventilator-associated pneumonia and
other codes specific for HAP as previously done in a study by Giuliano
et al.21 In a study by Nash et al., UTIs, pneumonia and bloodstream
infections have also been found to be prevalent HAI in ST-segment
elevated myocardial infarction (STEMI) patients, accounting for 6.0%,
4.6%, and 2.6% of STEMI patients aged older than 18 years,
respectively.22
Another observation made in our study was that the incidence of
NI has been decreasing in patients admitted with STEMI-CS over
10 years from 2005 to 2014. On the other hand, the incidence of HAI
has been increasing for patients with CS since 2008 according to
Miller et al..23 The incidence of HAI, however, did not change for
patients admitted with acute myocardial infarction or CABG. These
differences highlight the increasing need for studies focusing on NI
susceptibility and prevention for both acute myocardial infarction
and CS.
Truffa et al. explored the incidence and outcomes of infections in
patients with STEMI treated with PCI and found that the main loca-
tion of the infection was in the bloodstream. Additionally, compared
to those without infection, STEMI patients with infection had more
comorbidities.24 Our study comparing STEMI-CS patients with NI and
those without NI also showed that STEMI-CS patients with NI were
likely to have more comorbidities than those without. Moreover, in
our study, increasing length of hospital stay was found to be associ-
ated with NI. This was consistent with previous studies highlighting
the significance of hospital stay as a risk factor for developing infec-
tions.25,26 A retrospective cohort by Jeon et al. found that among
113,893 admissions, there was a nonlinear increase in the incidence
of bloodstream related infection. This increase was found to be higher
among sicker patients who required higher level of care.27
In our analysis, patients admitted with STEMI-CS whose hospital
stay was complicated with a NI had an 11% independent increase risk
of mortality. This increase is magnified when patients were diag-
nosed with sepsis during their admission (OR: 2.95; 95% CI: 2.72-
3.20). This finding was also highlighted in a study by Kohsaka et al.
where culture-positive patients with acute myocardial infarction
complicated by CS were at higher risk of mortality.28 Moreover, a
large prospective study by Vught et al. found that sepsis-associated
nosocomial infections were associated with 15-21% increased risk of
mortality; however, only 2% were specifically attributable to NI. This
showed that the difference in mortality was more related to an
advanced illness severity since admission.29 In the NIS database,
patients with STEMI-CS whose hospital stay was complicated with
sepsis are considered of a higher severity illness compared to those
without sepsis and thus explains the higher mortality rates among
those with NI and sepsis. Because different types of pMCS have been
used in the setting of CS,30 we also sought to investigate the associa-
tion between NI and type of pMCS used in STEMI-CS patients. The
incidence of death was lower in patients on pMCS compared to those
not on any pMCS (20.6% vs 23.5%, p < 0.001); however, higher mor-
tality rates were observed among those with sepsis and on any pMCS
(41.0% vs 36.8%, p = 0.009). A similar observation by Paoli et al. found
that increasing sepsis severity was associated with higher mortality
and increasing cost of hospitalization.31 A retrospective study by
Schmidt et al. explored how NI impacted adult patients receiving
venoarterial ECMO (VA-ECMO) for refractory CS. They defined
patients with acute refractory CS if the following signs were present:
“evidence of tissue hypoxia concomitant with adequate intravascular
volume and sustained hypotension and reduced cardiac index
(<2.2L/min/m2) despite infusion of high-dose catecholamines (epi-
nephrine >0.2mg/kg/min or dobutamine >20mg/kg/ min § norepi-
nephrine >0.2 mg/kg/min).”6 The definition of a NI set by Schmidt
et al. complied with the definition set by the Centers for Disease Con-
trol and Prevention National Nosocomial Infections Surveillance Sys-
tem. In this study by Schmidt el al., infected patients had longer
hospital stays, which was also shown in our study. The authors also
found that a NI with severe sepsis or septic shock was an indepen-
dent predictor of mortality in patients receiving peripheral VA-
ECMO.32 NI-associated sepsis was also evident among 61.5% of
deceased STEMI-CS patients placed on ECMO in our study after sub-
group analysis. However, in our analysis, NI were not found to be
independent predictors of mortality among patients on ECMO. This
can be attributed to an already elevated mortality rate among ECMO
patients. Sepsis was also reported in patients with CS complicating
acute myocardial infarction, particularly in those who were placed on
prolonged IABP.32 This finding was consistent with findings from our
study demonstrating that NI-associated sepsis was found in 38.6% of
deceased STEMI-CS patients placed on IABP.
Study limitations
This study has several limitations, particularly because this was a
retrospective analysis of a large database. One of the main limitations
of this study is the inability to draw conclusions related to the time to
event of a NI. Therefore, this study used ICD-9 codes to identify NI,
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allowing for potential coding errors. Another reason why coding
errors are a potential limitation in this study is because of the inabil-
ity to distinguish between infections that were nosocomial in origin
and those that were not nosocomial. However, to fulfill the definition
of NI, we excluded patients who stayed less than three days in the
hospital.
Other limitations include inability to determine causality for
length of hospital stay and NI, and lack of hospitals reporting NI.
Bond et al. explores two missions that were started by the United
States government, the “2009 HHS Action Plan to Prevent Health-
care-Associated Infections” and the “2011 Partnership for Patients”
to prevent NI-related infections.33-35 One of these plans included pre-
venting reimbursement to hospitals with higher rates of NIs as a sign
of low quality of care.36 This might decrease hospital incentives in
reporting NI and thus could explain the low sensitivity of NI-related
ICD-9/10 coding as highlighted by various literature.33,34,36 Moreover,
in a study by Meier et al., the authors examined the mandatory
reporting of healthcare-associated infections (HAI) by different states.
Different states have different laws for reporting HAI. This discrep-
ancy further allows a hospital, for which these laws do not apply, to
underreport NI and mitigate any financial impact NI may have on the
hospital itself.37 Another limitation of this study is that the NIS data-
base does not provide objective measures, such as vital signs, ejection
fraction reports, cardiac catheterization and angiographic results, as
well as laboratory data (ie, troponin, brain natriuretic peptide, etc.).
Because data used for this study only captured STEMI-CS admissions
from 2005 to 2014, we may have missed admissions outside this
period. Despite these limitations, the analysis was performed on a
large sample size from the NIS database. Lack of reporting bias found
in retrospective studies also strengthens our analysis. The NIS also
uses internal and external quality control measures to reduce coding
errors. Additionally, the ICD-9 codes have been previously validated
to encompass CS patients in the setting of myocardial infarction,38,39
and specifically in STEMI-CS patients.40
Conclusions
To the best of our knowledge, this is the largest study to date
demonstrating the association between NI and STEMI-CS. This study
provided insight into how mortality in STEMI-CS patients who devel-
oped NI varied depending on the type of pMCS used. Of noteworthy
importance, STEMI-CS patients who developed NI were at greater
odds of in-hospital mortality. Increasing length of hospital stay was
the strongest association with developing a NI. The significant impact
of NI on mortality, length of hospital stay, and hospitalization costs in
STEMI-CS should prompt hospitals to develop system-based algo-
rithms to rapidly detect, document, manage, and prevent NI in
patients with STEMI-CS.
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